The FDA has approved bevacizumab-bvxr (Zirabev, Pfizer), a biosimilar to bevacizumab (Avastin, Genentech/Roche), for the treatment of five types of cancer. These cancers include metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic...